Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Advertisement
Advertisement
Trending on OncLive
1
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
2
Dr Khushman on the Rationale for Investigating INCA33890 in MSS/pMMR mCRC
3
Iberdomide Plus Daratumumab/Dexamethasone Improves MRD-Negative CR vs DVd in Relapsed/Refractory Myeloma
4
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
5